Clinical impact of multidrug-resistant bacteria in older hospitalized patients with community-acquired urinary tract infection

BMC Infect Dis. 2021 Dec 7;21(1):1232. doi: 10.1186/s12879-021-06939-2.

Abstract

Introduction: Previous studies have described some risk factors for multidrug-resistant (MDR) bacteria in urinary tract infection (UTI). However, the clinical impact of MDR bacteria on older hospitalized patients with community-acquired UTI has not been broadly analyzed. We conducted a study in older adults with community-acquired UTI in order to identify risk factors for MDR bacteria and to know their clinical impact.

Methods: Cohort prospective observational study of patients of 65 years or older, consecutively admitted to a university hospital, diagnosed with community-acquired UTI. We compared epidemiological and clinical variables and outcomes, from UTI due to MDR and non-MDR bacteria. Independent risk factors for MDR bacteria were analyzed using logistic regression.

Results: 348 patients were included, 41.4% of them with UTI due to MDR bacteria. Median age was 81 years. Hospital mortality was 8.6%, with no difference between the MDR and non-MDR bacteria groups. Median length of stay was 5 [4-8] days, with a longer stay in the MDR group (6 [4-8] vs. 5 [4-7] days, p = 0.029). Inadequate empirical antimicrobial therapy (IEAT) was 23.3%, with statistically significant differences between groups (33.3% vs. 16.2%, p < 0.001). Healthcare-associated UTI variables, in particular previous antimicrobial therapy and residence in a nursing home, were found to be independent risk factors for MDR bacteria.

Conclusions: The clinical impact of MDR bacteria was moderate. MDR bacteria cases had higher IEAT and longer hospital stay, although mortality was not higher. Previous antimicrobial therapy and residence in a nursing home were independent risk factors for MDR bacteria.

Keywords: Inadequate empirical antimicrobial therapy; Older adults; Outcomes; Risk factor.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacteria
  • Community-Acquired Infections* / drug therapy
  • Community-Acquired Infections* / epidemiology
  • Cross Infection* / drug therapy
  • Drug Resistance, Multiple, Bacterial
  • Humans
  • Retrospective Studies
  • Risk Factors
  • Urinary Tract Infections* / drug therapy
  • Urinary Tract Infections* / epidemiology

Substances

  • Anti-Bacterial Agents